Growing public concern with the rise in drug prices has been a catalyst for a rethink of drug pricing and market access. Government organisations, patient groups and others are discussing ways to measure the cost effectiveness of new drugs in order to guide decision-making and make sure that the best medicines reach patients at affordable prices. This meeting will discuss how manufacturers plan to limit future price increases, and how policymakers are dealing with the tension between supporting innovation and keeping within national healthcare budgets. Attendees will get a detailed review of the payer landscape and how they can develop a successful market access strategy.
